Matinas BioPharma Announces Board and Executive Changes
Ticker: MTNB · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
Related Tickers: MTNB
TL;DR
Matinas BioPharma (MTNB) shakes up its board and exec pay structure.
AI Summary
Matinas BioPharma Holdings, Inc. announced on January 21, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may impact future performance.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- January 21, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing states that directors have been elected, but their names are not provided in this summary.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements, but the specific details are not included in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 21, 2025.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2025-01-24 17:15:39
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-003632.txt ( ) — 206KB
- mtnb-20250121.xsd (EX-101.SCH) — 3KB
- mtnb-20250121_lab.xml (EX-101.LAB) — 33KB
- mtnb-20250121_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: January 24, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-